Evidence map›Paper›PMID 40964095›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Effect of

Ling Wei, Tao Wang, Yongmei Hu, Qibing Xie

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ling Wei（ 610041） Department of General Practice, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region, Chengdu 610041, China.ORCID 0000-0001-5105-7902
Tao Wang（ 610041） Department of General Practice, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region, Chengdu 610041, China.
Yongmei Hu（ 610041） Department of General Practice, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region, Chengdu 610041, China.
Qibing Xie（ 610041） Department of General Practice, Hospital of Chengdu Office of People's Government of Xizang Autonomous Region, Chengdu 610041, China.ORCID 0000-0002-6727-1839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the effect of cytochrome P450 3A5 ( Methods: Patients with active LN attending the outpatient clinic of the Department of Rheumatology and Immunology, West China Hospital, Sichuan University were enrolled. Their Results: In the LN patient subgroups receiving TAC at the same initial dose, the cumulative remission rate of patients with the GG genotype was higher than that of patients with the AA+GA genotype, but only in the 0.05 mg/(kg·d) initial dose group, the difference in cumulative remission rate between the two genotypes was statistically significant ( Conclusion: The efficacy of TAC in treating LN patients is correlated with

Indexed as

Cytochrome P-450 CYP3AImmunosuppressive AgentsLupus NephritisPolymorphism, GeneticTacrolimusAdultFemaleGenotypeHumansMaleMiddle AgedPrognosisYoung AdultCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimusCYP3A5 gene polymorphismLupus nephritisTacrolimus blood drug concentration

Identifiers

PMID40964095
PMCPMC12439663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.